Rani Therapeutics Holdings, Inc. (RANI) stock

RANINasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 2/3044% above fair value

$0.53+0.00 (+0.21%)

Close on Nov 13, 2026Market cap $73.36MP/E –Yield –

Rani Therapeutics EPS

Diluted earnings per share is net income divided by the share count including options and convertible securities.

For fiscal 2025 it was -$0.45. The highest annual figure on record is -$0.43 in fiscal 2021.

Period	Period end	Value	Change
FY2025	Dec 31, 2025	-$0.45	–
FY2024	Dec 31, 2024	-$1.05	–
FY2023	Dec 31, 2023	-$1.33	–
FY2022	Dec 31, 2022	-$1.28	–
FY2021	Dec 31, 2021	-$0.43	–

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q3 FY2026	Sep 30, 2026	-$0.04	–
Q2 FY2026	Jun 30, 2026	-$0.04	–
Q1 FY2026	Mar 31, 2026	-$0.04	–
Q3 FY2025	Sep 30, 2025	-$0.12	–
Q2 FY2025	Jun 30, 2025	-$0.18	–
Q1 FY2025	Mar 31, 2025	-$0.22	–
Q3 FY2024	Sep 30, 2024	-$0.24	–
Q2 FY2024	Jun 30, 2024	-$0.26	–
Q1 FY2024	Mar 31, 2024	-$0.29	-187.9%
Q3 FY2023	Sep 30, 2023	-$0.36	-216.1%
Q2 FY2023	Jun 30, 2023	-$0.37	-227.6%
Q1 FY2023	Mar 31, 2023	-$0.33	–
Q3 FY2022	Sep 30, 2022	$0.33	–
Q2 FY2022	Jun 30, 2022	$0.31	–
Q1 FY2022	Mar 31, 2022	$0.29	–
Q3 FY2021	Sep 30, 2021	-$0.16	–
Q2 FY2021	Jun 30, 2021	-$0.12	–
Q2 FY2020	Jun 30, 2020	-$0.06	–

Parsed from the XBRL in Rani Therapeutics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing